MIRA PHARMACEUTICALS INC

MIRANASDAQ

🏆 #3560 by market capEarnings Sep 2US Equity

$0.78▲ $0.01 (+1.37%)

🌙 After hours$0.79▲ 1.54%Regular close · extended-hours price shown

1h—

24h▲ 1.4%

7d—

14d—

30d—

1y—

🏦Market Cap

$33M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

No chart data available for MIRA.

Trading Snapshot

Day Range: $0.77 – $0.78
52-Week Range: $0.60 – $2.45
Volume: $2.14B
Avg Volume: $1.45B
Shares Outstanding: 42.0M
Next Earnings: Oct 24, 2026

Fundamentals Snapshot

Annual Revenue: $6M
Last Q Revenue: $1M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-0.32
Dividend Yield: —

Why Investors Own MIRA

✓High-growth profile — revenue up +0.0% YoY with expanding US Equity exposure.
✓Healthy economics — 47% gross margin and 27% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$6M▲ +3.0% YoY

Gross Margin (TTM)

46.6%▲ +0.4% YoY

Operating Income (TTM)

$898,671▲ +3.0% YoY

Free Cash Flow (TTM)

$2M▲ +3.0% YoY

About MIRA PHARMACEUTICALS INC

MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.

🦦